Advanced Wound Care in Dermatology: The Executive Brief
Dermatologists don’t need to enter wound care — many already are. Here’s why that matters, and how NuVida and Atlas|CD help you build on it deliberately.
Dermatologists Don’t Need to Enter Wound Care. They’re Already In It.
Dermatology already manages skin failure across a spectrum — from a surgical defect to chronic ulceration in a medically complex patient. What’s often missing is a deliberate pathway for the wounds that don’t resolve on their own.
Advanced wound management begins with identifying why a wound isn’t progressing — not simply selecting a product.
Where It Intersects With Dermatology
Six clinical contexts already inside a typical dermatology panel.
Mohs & Surgical Dermatology
Surgical defects sometimes call for closure options beyond primary repair alone.
Chronic Wounds
A wound that stalls warrants a structured reassessment — not just a new dressing.
Lower Extremity Dermatology
Venous disease and related findings often present to dermatology first.
Complex & Atypical Wounds
Unclear etiology deserves dermatologic evaluation before a plan is set.
Post-Procedural Wounds
Biopsy and excision sites occasionally heal slower than expected.
Medically Complex Patients
Older and immunosuppressed patients carry a higher risk of impaired healing.
Advanced Wound Care Through an Enterprise Lens
For medical directors, COOs, CFOs, and platform leadership, the opportunity breaks into four parts.
Clinical
A consistent, defensible pathway for evaluating and managing appropriate wounds.
Operational
One ordering, verification, and documentation workflow at every location.
Patient
Continuity of care inside a relationship patients already trust.
Enterprise
Infrastructure built once, deployed everywhere — one location or fifty.
Why Now?
Trade press has covered a maturing wave of dermatology PE consolidation, a persistent Mohs-surgeon shortage, and an aging patient population with more wound-relevant comorbidities. None of it requires a group to become a wound-care company — it rewards the ones building a standardized pathway before they’re forced to.
A Changing Environment
Reimbursement and regulatory policy for skin substitutes continues to evolve; specifics vary by payer and are outside the scope of this page. What doesn’t change: documentation, verified eligibility, and a consistent process behind every order.
General industry context, not financial, legal, or coding advice.
A clinical capability becomes a scalable service line only when the workflow can be repeated consistently across providers and locations.
The NuVida Difference
Not tissue shipped to a physician. Science, tissue, technology, workflow, and support, working together.
Quality Assurance
Section 361 HCT/Ps processed by AATB-accredited RegenTX Partners. NuVida holds its own FDA Tissue License (FEI# 3027320971).
Science-Backed
Full-thickness constructs retain all three native layers. Peer-reviewed characterization documents the structural difference — not a healing claim.
Powered by Atlas|CD
Ordering, verification, documentation, and lot tracking in one platform — not fax and phone tag.
Clinician Focused
Built to remove administrative friction, from 24-hour IVR turnaround to automatic notifications.
Patient Driven
The objective stays constant regardless of scale: responsible, well-documented care.
Science & Evidence
The tissue itself, examined structurally — not just described.
Placental tissue is a natural, three-layer structure. Full-thickness allografts — caregraFT™ and completeFT™ — retain all three native layers; carePATCH™ is a dual-layer amniotic allograft. Peer-reviewed characterization (Singh et al., International Journal of Molecular Sciences, 2025) found tri-layer constructs are several times thicker and contain substantially more total protein — a structural finding, not a claim about comparative healing.
Illustrative comparison of tissue configuration — not to scale. Structural finding per Singh et al., International Journal of Molecular Sciences, 2025.
The tissue is only one part of the solution. Evidence, workflow, technology, and support determine whether a program can operate effectively.
One Clinical Opportunity. One Operational Workflow.
Powered by Atlas|CD — the same pipeline your team and ours both see.
Built Beyond the Single Practice
The same infrastructure runs whether you’re coordinating one location or a hundred providers.
Building the Service Line
A general framework NuVida can guide a practice through — not a guaranteed timeline.
Evaluate & Plan
Assess your patient population, identify relevant pathways, and set protocols for when advanced management applies.
Build & Launch
Educate providers and staff, configure Atlas|CD workflows, and launch at a single pilot location.
Measure & Expand
Track performance, refine the protocol, and expand where clinically and operationally appropriate.
What Dermatology Leaders Ask Us
Where does advanced wound care fit within dermatology?
Dermatology already manages skin failure across a spectrum — from surgical defects to chronic ulceration in medically complex patients. Advanced wound care is a set of tools for a subset of patients already within that scope, not a separate specialty to build from scratch.
How does this integrate with Mohs and surgical dermatology workflows?
It sits downstream of the surgical decision, not in place of it. Closure strategy remains a case-by-case clinical call; advanced allografts are one option a surgeon may weigh alongside standard closure techniques.
How are products ordered, and who handles insurance verification?
Directly through Atlas|CD — no fax, no phone tag. IVR requests are submitted in the patient’s profile and typically reviewed within 24 hours, with a clear approved, pending, or denied status.
How does this scale across multiple offices?
The same workflow runs at every location. Group and PE-backed practices get consolidated, role-based visibility across locations in Atlas|CD, while each site’s patient data stays private to that site.
What evidence supports the products?
caregraFT™ and completeFT™ are full-thickness, tri-layer allografts; carePATCH™ is dual-layer. Peer-reviewed characterization (Singh et al., 2025) documents structural differences between these configurations — see Science & Evidence above for specifics and caveats.
How are the tissues regulated?
caregraFT™, carePATCH™, and completeFT™ are HCT/Ps regulated under Section 361 and 21 CFR Part 1271 — not as FDA-approved biologics or devices. NuVida holds an FDA Tissue License for storage and distribution (FEI# 3027320971).
What training and support does NuVida provide?
Our team supports onboarding, walks staff through the ordering and verification workflow, and remains a direct point of contact by phone or email — not a general support queue.